Core Viewpoint - JingTai Technology (02228) has seen a stock increase of over 5% following the announcement of a significant clinical development milestone for the new generation PRMT5 inhibitor PEP08, which has received clinical trial approvals in Australia and Taiwan [1] Group 1: Clinical Development - JingTai Technology announced that the PRMT5 inhibitor PEP08 has achieved important clinical research milestones, receiving approvals from the Human Research Ethics Committee (HREC) in Australia, the Therapeutic Goods Administration (TGA), and the Taiwan Food and Drug Administration (TFDA) for clinical trials [1] - The initiation of Phase I clinical trials for PEP08 is imminent, marking a significant step in its development [1] Group 2: Financial Performance - JingTai Technology confirmed receipt of milestone payments related to the PEP08 project, contributing positively to its financial performance [1] - According to招商证券, the company's AI pharmaceutical business is steadily advancing, with a projected year-on-year growth rate of 615% in drug discovery business by the first half of 2025 [1] Group 3: Strategic Partnerships - The company has established long-term collaborations with leading global pharmaceutical companies such as Pfizer and Johnson & Johnson [1] - JingTai Technology has completed a pipeline cooperation agreement with DoveTree, with a total order scale of 5.99 billion USD, and has received an initial payment of 51 million USD as per the agreement [1] Group 4: Technological Advancements - The company has successfully expanded its technology platform across various fields, including new energy, agriculture, and industrial materials, by leveraging quantum physics computing, multimodal AI, and automation platforms [1]
晶泰科技涨超5% 助力智擎生技新药获临床实验审批 公司AI制药业务商业化稳步推进